Oppenheimer Maintains Outperform on Aptose Biosciences, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has maintained an Outperform rating on Aptose Biosciences (NASDAQ:APTO) but lowered the price target from $50 to $15.

August 11, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Oppenheimer has maintained an Outperform rating on Aptose Biosciences but lowered the price target from $50 to $15.
The lowering of the price target by such a significant amount could negatively impact investor sentiment and potentially lead to a short-term decrease in the stock price. However, the maintained Outperform rating suggests that the analyst still sees potential in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100